JP2017505321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505321A5 JP2017505321A5 JP2016550218A JP2016550218A JP2017505321A5 JP 2017505321 A5 JP2017505321 A5 JP 2017505321A5 JP 2016550218 A JP2016550218 A JP 2016550218A JP 2016550218 A JP2016550218 A JP 2016550218A JP 2017505321 A5 JP2017505321 A5 JP 2017505321A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutically acceptable
- cancer
- composition according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 55
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 229940124647 MEK inhibitor Drugs 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 20
- 229940124783 FAK inhibitor Drugs 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 15
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 claims description 9
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 9
- 229960004066 trametinib Drugs 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 229960002271 cobimetinib Drugs 0.000 claims description 7
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 4
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000007538 neurilemmoma Diseases 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229950002592 pimasertib Drugs 0.000 claims description 4
- 206010039667 schwannoma Diseases 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 3
- -1 pimasertiv Chemical compound 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 2
- 241000272186 Falco columbarius Species 0.000 claims description 2
- 102100039788 GTPase NRas Human genes 0.000 claims description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 2
- 208000037844 advanced solid tumor Diseases 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 238000009175 antibody therapy Methods 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229940125683 antiemetic agent Drugs 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 238000009093 first-line therapy Methods 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 238000012224 gene deletion Methods 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 230000006607 hypermethylation Effects 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 208000037843 metastatic solid tumor Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 208000025189 neoplasm of testis Diseases 0.000 claims description 2
- 206010061311 nervous system neoplasm Diseases 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims description 2
- 208000022032 neurofibromatosis type 2 Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000011301 standard therapy Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937253P | 2014-02-07 | 2014-02-07 | |
| US61/937,253 | 2014-02-07 | ||
| PCT/US2015/014843 WO2015120289A1 (en) | 2014-02-07 | 2015-02-06 | Methods and compositions for treating abnormal cell growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020034703A Division JP7289807B2 (ja) | 2014-02-07 | 2020-03-02 | 異常な細胞成長を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505321A JP2017505321A (ja) | 2017-02-16 |
| JP2017505321A5 true JP2017505321A5 (https=) | 2018-03-22 |
Family
ID=53778481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550218A Withdrawn JP2017505321A (ja) | 2014-02-07 | 2015-02-06 | 異常な細胞成長を処置するための方法および組成物 |
| JP2020034703A Active JP7289807B2 (ja) | 2014-02-07 | 2020-03-02 | 異常な細胞成長を処置するための方法および組成物 |
| JP2022098159A Active JP7578643B2 (ja) | 2014-02-07 | 2022-06-17 | 異常な細胞成長を処置するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020034703A Active JP7289807B2 (ja) | 2014-02-07 | 2020-03-02 | 異常な細胞成長を処置するための方法および組成物 |
| JP2022098159A Active JP7578643B2 (ja) | 2014-02-07 | 2022-06-17 | 異常な細胞成長を処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9962385B2 (https=) |
| EP (2) | EP3698790B1 (https=) |
| JP (3) | JP2017505321A (https=) |
| DK (2) | DK3102232T3 (https=) |
| ES (2) | ES2779975T3 (https=) |
| FI (1) | FI3698790T3 (https=) |
| WO (1) | WO2015120289A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201805890QA (en) * | 2014-01-09 | 2018-08-30 | Verastem Inc | Compositions and methods for treatment of abnormal cell growth |
| JP2018519327A (ja) | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | 治療用組成物、組合せ物および使用の方法 |
| WO2018148666A1 (en) * | 2017-02-13 | 2018-08-16 | University Of Pittsburgh-Of The Commonwealth Systems Of Higher Education | Focal adhesion kinase inhibitor as a therapeutic agent in diabetes |
| IL257225A (en) * | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| JP2022525616A (ja) * | 2019-03-19 | 2022-05-18 | ユン，キュソン | 細胞サンプルの評価のための方法およびシステム |
| WO2020236620A1 (en) * | 2019-05-17 | 2020-11-26 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of cancer to ferroptosis-inducing therapies |
| US12521394B2 (en) | 2019-06-21 | 2026-01-13 | Pattern Computer, Inc. | Therapeutic compositions and methods for treating cancers |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| AU2020388848A1 (en) * | 2019-11-18 | 2022-05-26 | Inxmed (Nanjing) Co., Ltd. | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation |
| US11666574B2 (en) * | 2019-11-27 | 2023-06-06 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| CN115279376A (zh) * | 2020-01-31 | 2022-11-01 | 维瑞斯特姆股份有限公司 | 用于治疗异常细胞生长的组合疗法 |
| MX2022009612A (es) | 2020-02-05 | 2022-09-19 | Inxmed Nanjing Co Ltd | Combinacion de bi853520 con farmacos quimioterapeuticos. |
| EP4288057A4 (en) * | 2021-02-05 | 2025-03-12 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| TW202313044A (zh) | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0810411B8 (pt) | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| KR101489045B1 (ko) * | 2009-10-12 | 2015-02-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합 |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| AR084216A1 (es) | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| WO2013170066A1 (en) * | 2012-05-09 | 2013-11-14 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Peptides for the treatment of cancer |
| WO2013182668A1 (en) * | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| KR20150067323A (ko) | 2012-10-12 | 2015-06-17 | 글락소스미스클라인 엘엘씨 | 조합물 |
-
2015
- 2015-02-06 ES ES15746033T patent/ES2779975T3/es active Active
- 2015-02-06 ES ES20154659T patent/ES2945387T3/es active Active
- 2015-02-06 WO PCT/US2015/014843 patent/WO2015120289A1/en not_active Ceased
- 2015-02-06 FI FIEP20154659.5T patent/FI3698790T3/fi active
- 2015-02-06 EP EP20154659.5A patent/EP3698790B1/en active Active
- 2015-02-06 JP JP2016550218A patent/JP2017505321A/ja not_active Withdrawn
- 2015-02-06 DK DK15746033.8T patent/DK3102232T3/da active
- 2015-02-06 US US15/116,712 patent/US9962385B2/en active Active
- 2015-02-06 EP EP15746033.8A patent/EP3102232B1/en active Active
- 2015-02-06 DK DK20154659.5T patent/DK3698790T3/da active
-
2018
- 2018-04-02 US US15/943,229 patent/US10406158B2/en active Active
-
2019
- 2019-07-23 US US16/519,605 patent/US20200147080A1/en not_active Abandoned
-
2020
- 2020-03-02 JP JP2020034703A patent/JP7289807B2/ja active Active
-
2022
- 2022-06-17 JP JP2022098159A patent/JP7578643B2/ja active Active
- 2022-11-17 US US17/989,006 patent/US20230321097A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505321A5 (https=) | ||
| FI3698790T3 (fi) | Menetelmiä epänormaalin solukasvun hoitamiseksi | |
| JP2020514311A5 (https=) | ||
| CN102014624A (zh) | 治疗肺癌的吡铂和氨柔比星 | |
| JP2011144190A (ja) | 抗癌剤の効果増強剤 | |
| JP2016536352A5 (https=) | ||
| JP2021520406A5 (https=) | ||
| JP2020517696A5 (https=) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2019506392A5 (https=) | ||
| Lee et al. | Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer | |
| JP2017516827A5 (https=) | ||
| JP2014530181A5 (https=) | ||
| CA2514227A1 (en) | Combination therapy of zd6474 with 5-fu or/and cpt-11 | |
| CN110290802A (zh) | [6r]-mthf-在基于5-氟尿嘧啶的化学疗法中的有效叶酸替代物 | |
| JP2013508295A5 (https=) | ||
| Breithaupt et al. | Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients | |
| JPWO2019196764A5 (https=) | ||
| JP2018511642A5 (https=) | ||
| Chua et al. | Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary | |
| JP2013506626A5 (https=) | ||
| JPWO2019161054A5 (https=) | ||
| CN115243719A (zh) | CTB006与Ponatinib联合应用 | |
| He et al. | Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula | |
| Bi et al. | P47. 18 Almonertinib with radiotherapy vs concurrent chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC (ADVANCE Trial) |